Drug intelligence / Profile preview

GT820

Development stage: Preclinical
Lead developer: Gluetacs Therapeutics
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Oral

Overview

GT820 is an orally bioavailable small molecule proteolysis-targeting chimera (PROTAC) currently under development by Gluetacs Therapeutics. It is specifically designed to treat hepatocellular carcinoma (HCC) by inducing the targeted degradation of a pathogenic protein. While the specific molecular target of GT820 has not been publicly disclosed by the developer, the compound utilizes the PROTAC mechanism to recruit an E3 ubiquitin ligase to a target protein, leading to its ubiquitination and subsequent degradation by the proteasome. As of early 2024, GT820 is in the preclinical stage of development.

Beyond the preview

Go deeper on GT820.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT820.

Explore the full profile